Mondo Visione Worldwide Financial Markets Intelligence

FTSE Mondo Visione Exchanges Index:

News Centre

CCData-468x60x2.jpg BT_Radianz_468x60_Jul23

  • Announcing The Launch Of “JPxData Portal (Beta Version)”, A Portal Site Comprehensively Covering Data Provided By JPX Group, Etc.

    Date 26/08/2024

    Today, JPX Market Innovation & Research, Inc. (hereinafter referred to as “JPXI”) launched “JPxData Portal (beta version)” (hereinafter referred to as “Website”), a portal site that comprehensively introduces data provided by Japan Exchange Group, Japan Exchange Group companies and partner companies (hereinafter referred to as “JPX Group, etc.”).

  • 886 Shanghai Stock Exchange-Listed Companies Disclose Semi-Annual Reports, With 509 Reporting Good Performances

    Date 26/08/2024

    According to STCN, as of August 26, 886 companies listed on the Shanghai Stock Exchange (SSE) had disclosed their semi-annual performances. Their combined operating revenue reached RMB 7.86 trillion, increasing by 2.3% year on year, and the combined net profit attributable to their parent companies amounted to RMB 679 billion, up 6% year on year. Out of the total, 509 companies reported good performances, representing approximately 60%. The performance growth of 105 companies exceeded 100%, and that of 164 companies surpassed 50%. By sector, numerous pillar industries including non-ferrous metals, transportation, automobile tires, power, and integrated circuits performed well.

  • Shanghai Stock Exchange: Twenty-Two Innovative Drug Companies On The Star Market Release Semi-Annual Reports, Showcasing A Combined Operating Revenue Of Rmb 28.4 Billion

    Date 26/08/2024

    So far, 22 innovative drug companies listed on the STAR Market have released their semi-annual performance data, marking that the disclosure process for such companies on the STAR Market is halfway complete. The combined semi-annual operating revenue of these companies reached RMB 28.4 billion, representing a 69.21% increase year on year. The net profit attributable to their parent companies arrived at RMB 1.49 billion, shifting from loss to profit when compared with the same period last year, with more than half of these companies witnessing improved profitability. In general, innovative drug companies listed on the STAR Market are swiftly converting their clinical advantages into industrial benefits and are progressively moving towards commercialization or cashing period of their licensing out both domestically and internationally. Overall, their performance is evidently on an upward trajectory.

  • SET: mai-listed Companies Post Robust H1/2024 Net Profit

    Date 26/08/2024

    • Mai-listed firms’ H1 sales up 7.7% y-o-y to THB 104.3 bln
    • H1 operating profit up 44.8% y-o-y to THB 8.35 bln
    • H1 net profit up 80.5% y-o-y to THB 6.10 bln

  • SET: Thai Listed Companies Report Continued Earnings Growth In Q2, Propelled By Tourism And Oil-Related Sectors

    Date 26/08/2024

    • SET-listed firms’ H1 sales up 6.3% y-o-y to THB 8.96 trln
    • H1 core operating profit up 18.7% y-o-y to THB 922.74 bln
    • H1 net profit up 9.7% y-o-y to THB 519.31 bln

Confinity_sky1-min.gif MV 120 X 600 Hard to Reach BT_Radianz_120x600_Jul23.jpg